Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Sunlenca

Sunlenca 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 22

HOS-148337 · Präparat HOS-099874

Medicinal product by therapeutic Effects on concentrations. Recommendation concerning areas Mean percent change in AUC, co-administration with Sunlenca Cmax ANTIMYCOBACTERIALS Rifampicina,b,c (600 mg once daily) Lenacapavir: Co-administration is AUC: ↓84% contraindicated (see section 4.3). Cmax: ↓55% Rifabutin Interaction not studied. Co-administration is not recommended (see section 4.4). Co-administration of rifabutin may decrease lenacapavir plasma concentrations, which may result in loss of therapeutic effect and development of resistance. ANTICONVULSANTS Carbamazepine Interaction not studied. Co-administration is Phenytoin contraindicated (see section 4.3) Co-administration of Oxcarbazepine carbamazepine, oxcarbazepine, Co-administration is not Phenobarbital phenobarbital, or phenytoin with recommended (see section 4.4). lenacapavir may decrease lenacapavir plasma concentrations, Alternative anticonvulsants should which may result in loss of be considered. therapeutic effect and development of resistance. HERBAL PRODUCTS St. John’s wort (Hypericum Interaction not studied. Co-administration is perforatum) contraindicated (see section 4.3). Co-administration of St. John’s wort may decrease lenacapavir plasma concentrations, which may result in loss of therapeutic effect and development of resistance.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)